This study is conducted from year 2019-2022 in Gujarat Cancer Society medical college and research center, Ahmedabad. Out of total 275 patients on drug resistant TB regimen (all oral longer, shorter injectable and mono H) seen in opd, 55 patients presented with adverse drug reaction. Most commonly affected age group was 20-40 yr old. During the course of treatment 32.7% required hospitalization, of which 29% were admitted in ward, rest required ICU care. Maximum ADR occurred in first 30 days of starting ATT. Drug had to be withdrawn in 41.81% and in 32.7%, offending agent was withdrawn permanently. There was no mortality during the study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijtb.2023.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.
Curr Top Behav Neurosci
January 2025
Department of Neurobiology, University of Maryland, School of Medicine, Baltimore, MD, USA.
In the last two decades, the endocannabinoid system has emerged as a crucial modulator of motivation and emotional processing. Due to its widespread neuroanatomical distribution and characteristic retrograde signaling nature, cannabinoid type I receptors and their endogenous ligands finely orchestrate somatic and axon terminal activity of dopamine neurons. Owing to these unique features, this signaling system is a promising pharmacological target to ameliorate dopamine-mediated drug-seeking behaviors while circumventing the adverse side effects of, for instance, dopaminergic antagonists.
View Article and Find Full Text PDFSuccessful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study.
Dermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Evaluating duloxetine for pruritus and psychiatric comorbidities in lichen simplex chronicus.
Arch Dermatol Res
January 2025
The Dermatology Department of the Central Military Hospital of the Ministy of Defense, Baku, Azerbaijan.
The use of antidepressant medications in the treatment of lichen simplex chronicus (LSC) also known as neurodermatitis, is not well-documented in the literature. The primary aim of our study is to evaluate the impact of duloxetine 30 mg on the quality of life in patients with LSC, focusing on both pruritus and psychopathological aspects. The secondary aim is to investigate the relationship between LSC and anxiety and depression.
View Article and Find Full Text PDFImpulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDFOcrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
J Neurol
January 2025
Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!